142 related articles for article (PubMed ID: 2684694)
21. The effect of subcutaneous infusion versus subcutaneous injections of a somatostatin analogue (SMS 201-995) on the diurnal GH profile in acromegaly.
Timsit J; Chanson P; Larger E; Duet M; Mosse A; Guillausseau PJ; Harris AG; Moulonguet M; Warnet A; Lubetzki J
Acta Endocrinol (Copenh); 1987 Sep; 116(1):108-12. PubMed ID: 2889306
[TBL] [Abstract][Full Text] [Related]
22. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion.
Barkan AL; Beitins IZ; Kelch RP
J Clin Endocrinol Metab; 1988 Jul; 67(1):69-73. PubMed ID: 2897974
[TBL] [Abstract][Full Text] [Related]
23. Treatment of acromegaly with long acting somatostatin analogue SMS 201-995.
Horikawa R; Takano K; Hizuka N; Asakawa K; Sukegawa I; Hirose N; Horiba N; Kasono K; Masuda A; Ohba Y
Endocrinol Jpn; 1988 Oct; 35(5):741-51. PubMed ID: 3220051
[TBL] [Abstract][Full Text] [Related]
24. Octreotide treatment of acromegaly. A randomized, multicenter study.
Ezzat S; Snyder PJ; Young WF; Boyajy LD; Newman C; Klibanski A; Molitch ME; Boyd AE; Sheeler L; Cook DM
Ann Intern Med; 1992 Nov; 117(9):711-8. PubMed ID: 1416572
[TBL] [Abstract][Full Text] [Related]
25. A randomized study of SMS 201-995 versus bromocriptine treatment in acromegaly: clinical and biochemical effects.
Halse J; Harris AG; Kvistborg A; Kjartansson O; Hanssen E; Smiseth O; Djøsland O; Hass G; Jervell J
J Clin Endocrinol Metab; 1990 May; 70(5):1254-61. PubMed ID: 2186055
[TBL] [Abstract][Full Text] [Related]
26. Long term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly.
Tauber JP; Babin T; Tauber MT; Vigoni F; Bonafe A; Ducasse M; Harris AG; Bayard F
J Clin Endocrinol Metab; 1989 May; 68(5):917-24. PubMed ID: 2565913
[TBL] [Abstract][Full Text] [Related]
27. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.
Davies PH; Stewart SE; Lancranjan L; Sheppard MC; Stewart PM
Clin Endocrinol (Oxf); 1998 Mar; 48(3):311-6. PubMed ID: 9578821
[TBL] [Abstract][Full Text] [Related]
28. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995.
Lamberts SW; Uitterlinden P; Verschoor L; van Dongen KJ; del Pozo E
N Engl J Med; 1985 Dec; 313(25):1576-80. PubMed ID: 2866445
[TBL] [Abstract][Full Text] [Related]
29. Short term treatment of acromegaly with the somatostatin analog octreotide: the first double-blind randomized placebo-controlled study on its effects.
Fredstorp L; Harris A; Haas G; Werner S
J Clin Endocrinol Metab; 1990 Nov; 71(5):1189-94. PubMed ID: 2229278
[TBL] [Abstract][Full Text] [Related]
30. Body composition in active acromegaly during treatment with octreotide: a double-blind, placebo-controlled cross-over study.
Hansen TB; Gram J; Bjerre P; Hagen C; Bollerslev J
Clin Endocrinol (Oxf); 1994 Sep; 41(3):323-9. PubMed ID: 7955439
[TBL] [Abstract][Full Text] [Related]
31. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.
Shimatsu A; Teramoto A; Hizuka N; Kitai K; Ramis J; Chihara K
Endocr J; 2013; 60(5):651-63. PubMed ID: 23337477
[TBL] [Abstract][Full Text] [Related]
32. The response of serum growth hormone levels to the long-acting somatostatin analog SMS 201-995 in acromegaly.
Comi RJ; Gorden P
J Clin Endocrinol Metab; 1987 Jan; 64(1):37-42. PubMed ID: 2878009
[TBL] [Abstract][Full Text] [Related]
33. Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group.
Sassolas G; Harris AG; James-Deidier A
J Clin Endocrinol Metab; 1990 Aug; 71(2):391-7. PubMed ID: 2199479
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
Giusti M; Gussoni G; Cuttica CM; Giordano G
J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
[TBL] [Abstract][Full Text] [Related]
35. Medical management of acromegaly: effects of SMS 201-995 in 30 patients.
Pagani G; Montini M; Gianola D; Pagani MD; Tengattini F; Dominoni P; Ghilardi G; Cortesi L; Pedroncelli A; Tonnarelli GP
Endocrinol Exp; 1990 Mar; 24(1-2):175-85. PubMed ID: 2361459
[TBL] [Abstract][Full Text] [Related]
36. Somatostatin analog treatment of acromegaly: new aspects.
Lamberts SW; del Pozo E
Horm Res; 1988; 29(2-3):115-7. PubMed ID: 2900190
[TBL] [Abstract][Full Text] [Related]
37. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
[TBL] [Abstract][Full Text] [Related]
38. Administration of high-dose octreotide (Sandostatin) by continuous subcutaneous infusion for the treatment of acromegaly.
White MC; James RA; Chatterjee S; Mother M; Hall K; Dunne MJ; Baister ER; Kendall-Taylor P
Horm Res; 1990; 33 Suppl 1():13-8; discussion 18-9. PubMed ID: 1972690
[TBL] [Abstract][Full Text] [Related]
39. The effect of minisomatostatin on anomalous growth hormone responses in acromegaly.
Pieters GF; Smals AE; Smals AG; von Gennep JA; Kloppenborg PW
Acta Endocrinol (Copenh); 1987 Apr; 114(4):537-42. PubMed ID: 2883797
[TBL] [Abstract][Full Text] [Related]
40. Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995).
Caron P; Cogne M; Gusthiot-Joudet B; Wakim S; Catus F; Bayard F
Eur J Endocrinol; 1995 Mar; 132(3):320-5. PubMed ID: 7889181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
